pharmaphorum

JUNE 17, 2022

Paxlovid consists of two different drugs, nirmatrelvir 150mg tablets co-packaged with ritonavir 100mg tablets. The active drug is nirmatrelvir, a protease inhibitor, which helps keep the SARS-CoV-2 protein from replicating. In clinical trials, 5.6 How does the drug work?

Drugs 105

Drugs Clinical Trials Clinical Trials HR 105

XTalks

FEBRUARY 8, 2024

for a one-month supply Why it did so well: Jardiance belongs to a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors, inhibiting the SGLT2 protein in the kidneys to lead to the excretion of excess glucose through the urine. for a 2-pen package (0.6 & 1.2 for a 3-pen package (1.8 mg doses), or $815.27

Sales 52

Sales Insulin FDA Approval Drugs 52

The Pharma Data

OCTOBER 30, 2020

The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus’s spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population, as detailed in Science.

Production 52

Production Antibody Manufacturing Trials 52

XTalks

MARCH 28, 2024

Winrevair is an activin signaling inhibitor that binds to activin proteins that are overproduced in PAH. The proteins induce the walls of blood vessels to grow and thicken over time, stressing the heart to work harder to pump blood which can eventually lead to heart failure.

FDA Approval 81

FDA Approval Clinical Trials Clinical Trials Trials 81

The Pharma Data

OCTOBER 28, 2020

Results showed no significant difference in virologic or clinical efficacy between the REGN-COV2 high dose (8 grams) and low dose (2.4 Based on this finding, Regeneron is reviewing potential changes to dosing in the ongoing outpatient clinical trial given the current limited supply of REGN-COV2.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 5, 2020

(NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells.

Antibody 40

Antibody Production Trials Medicine 40

The Pharma Data

JANUARY 12, 2021

“Patients in our antibody cocktail outpatient clinical trial experienced significant reductions in virus levels and required fewer medical visits for COVID-19, suggesting the therapy can help reduce the current burden on hospitals and healthcare systems,” said George D.

Antibody 52

Antibody Production Manufacturing Clinical Trials 52